Navigation Links
Arete Therapeutics Initiates Phase IIa Clinical Trial for AR9281, a Novel s-EH Inhibitor to Treat Type 2 Diabetes
Date:2/10/2009

HAYWARD, Calif., Feb. 10 /PRNewswire/ -- Arete Therapeutics Inc. today announced the initiation of a Phase IIa clinical trial for AR9281, an orally- administered soluble epoxide hydrolase (s-EH) inhibitor being developed for the treatment of type 2 diabetes. S-EH is an enzyme involved in the metabolism of arachidonic acid, a key signaling molecule implicated in diabetes, hypertension and inflammatory disorders.

"Our AR9281 Phase II clinical trial program breaks new ground in two key areas. This is the first clinical study of a s-EH inhibitor in patients, and the first study designed to establish proof of concept that s-EH inhibition modulates glucose metabolism or blood pressure in patients with impaired glucose tolerance and hypertension," said James Sabry, M.D., Ph.D., President and Chief Executive Officer of Arete Therapeutics. "AR9281 has demonstrated an excellent safety profile and activity in multiple animal models of type 2 diabetes, and has the advantage of inhibiting a novel drug target that differentiates it from currently marketed diabetes medications. With this promising drug profile, AR9281 has the potential to provide safe and effective therapy for patients with type 2 diabetes either as monotherapy or in combination with existing treatment regimens."

The Phase IIa multicenter, double-blind, placebo-controlled study will enroll 150 pre-diabetic patients with impaired glucose tolerance, mild obesity and mild to moderate hypertension. All patients enrolled in the study will be treatment-naïve for type 2 diabetes medications. The trial will evaluate two schedules of AR9281 and placebo using a parallel design to determine the feasibility of twice-a-day dosing. Each patient will receive 28 days of treatment. Endpoints for the trial include safety, tolerability, reduction of blood pressure and various measures of glucose and lipid metabolism, with results expected in the first quarter of 2010.'/>"/>

SOURCE Arete Therapeutics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. CareTech Solutions Executive to Conduct Presentation on Creating a Healthy Revenue Cycle at AHIMA Convention and Exhibit
2. Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent
3. Arete Therapeutics Appoints Donald Santel to Board of Directors
4. CareTech Solutions Service Desk Equals Help Desk Plus
5. Nationally Recognized Diabetes Specialist Dr. Steven Edelman to Provide Educational Articles on Diabetes to MyCareTeam's Website Community
6. CareTech Solutions Named Best in KLAS for Extensive IT Outsourcing Services
7. EnovateIT Partners with CareTech Solutions to Create a Custom Product for Crittenton Hospital Medical Center, One of the Nation's Most Wired Hospitals
8. Prime Therapeutics Receives TIPPS Certification
9. Adams Respiratory Therapeutics to Celebrate 10th Anniversary of its Incorporation on September 12
10. Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
11. Lorus Therapeutics announces election of three new Directors and appoints a new Chairman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... As reported in a ... series, “Atlanta Plastic” is getting attention for moving outside traditional ethnic stereotypes when ... African-American cast of doctors and patients. Beverly Hills based plastic surgeon Payam Jarrah-Nejad, ...
(Date:8/3/2015)... ... August 03, 2015 , ... BESLER Consulting today ... B2B Awards. , The MarketingProfs Bright Bulb B2B Awards celebrate the best marketing, ... for the launch of their Readmissions Analytics product was selected as one of ...
(Date:8/3/2015)... ... August 03, 2015 , ... Catalent Pharma Solutions, the ... and consumer health products, today welcomed the announcement by OPKO Health that the ... for a new treatment for chronic kidney disease (CKD) and vitamin D insufficiency, ...
(Date:8/3/2015)... ... August 03, 2015 , ... The art of preparing and ... her grandmother’s side at a young age, Nasreen Zereshki was extremely eager to cook ... share her cookbook Recipes from My Persian Kitchen with the world. , Since Americans ...
(Date:8/3/2015)... ... 2015 , ... The U.S. Food and Drug Administration (FDA) recently approved a ... acid, which occurs naturally in the body and helps absorb and breakdown fat cells. ... the body. These are invasive procedures and very expensive for most people. Now with ...
Breaking Medicine News(10 mins):Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 2Health News:Article on Lifetime’s New “Atlanta Plastic” Reality Series Underlines the Diversity of Today’s Plastic Surgery Patients, Says Plastic Surgeon Dr. J 3Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 2Health News:Catalent’s OptiShell™ Technology is Delivery Platform for OPKO Health’s New Chronic Kidney Disease Treatment 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 2Health News:Dr. Ava Shamban to Offer the New Double Chin Treatment Kybella 3
... Ex-police officer and certified search & rescue manager won contest to ... , LOS ANGELES, June 17 Can ... of the late search and rescue dog and 9-11 hero, Trakr, ... 2009. BioArts International, a Northern California biotech company that is offering ...
... ... ... -- The IMTA and PATA recently signed a Memorandum of Understanding (MOU) to promote healthcare ... development of this high value sector and drive more integration between the travel and healthcare ...
... ... practice to a brand new state of the art location at 5044 Tennyson in Plano. ... Laser Surgery. , ... 2009 -- Dr. Bryan Selkin, the Chief Dermatologist of the Dermatology Center of Plano will be ...
... Two Cold Remedy Nasal Products Citing Commitment to Consumer Safety ... Matrixx Initiatives, Inc. (Nasdaq: MTXX ) has confirmed ... Food and Drug Administration about two of its 19 existing ... Cold Remedy Swabs. The warning letter cited consumer reports that ...
... June 16 Mammography has long been the standard for ... tissue can make tumors difficult to find. According to ... tissue are five times more likely to develop breast cancer. ... SI ) at: http://inr.mediaseed.tv/oneClip_C/?feed=KmAdskkAWyriUTQcX9fLjuG_zA0wEhsO ...
... PHILADELPHIA, June 16 United States Attorney Michael L. ... today announced the return of an indictment(1.) against Norian ... executives, Michael D. Huggins (Huggins), Thomas B. Higgins (Higgins), ... charging them for their involvement in conducting clinical trials ...
Cached Medicine News:Health News:BioArts International Clones 9-11 Hero Dog - Owner to Receive Five Cloned Puppies June 17 in Los Angeles 2Health News:BioArts International Clones 9-11 Hero Dog - Owner to Receive Five Cloned Puppies June 17 in Los Angeles 3Health News:The International Medical Travel Association (IMTA) and Pacific Asia Travel Association (PATA) sign MOU to Promote Healthcare Travel 2Health News:The International Medical Travel Association (IMTA) and Pacific Asia Travel Association (PATA) sign MOU to Promote Healthcare Travel 3Health News:New State of the Art Dermatology Center in Plano TX 2Health News:Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel 2Health News:Matrixx Initiatives Voluntarily Withdraws Zicam Cold Remedy Swabs, Zicam Cold Remedy Nasal Gel 3Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 2Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 3Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 4Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 5Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 6Health News:International Medical Device Maker; Four Executives Charged in Connection With Unlawful Clinical Trials 7
(Date:8/3/2015)... CAMBRIDGE, Mass. , Aug. 3, 2015 ... the company will host its Second Quarter 2015 Investor ... August 10.    The call will cover ... summary of second quarter 2015 financials. A press release ... will be issued the afternoon of Monday, August 10. ...
(Date:8/3/2015)... SAN FRANCISCO, Calif. , Aug. 3, 2015 ... for the treatment of cancer, today announced the ... Debanjan Ray , who previously ... alliance management, has been promoted to senior vice ... joining CytomX, Mr. Ray held positions as the ...
(Date:8/3/2015)... 3, 2015  Celsion Corporation (NASDAQ: CLSN ... a conference call to discuss its second quarter ... its development programs for ThermoDox®, its proprietary heat-activated ... technology platforms, TheraPlas™ and TheraSilence™, in immunotherapy and ... August 10, 2015. To participate in the call, ...
Breaking Medicine Technology:Merrimack Pharmaceuticals Announces Timing of Second Quarter 2015 Investor Conference Call 2CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3Celsion Corporation to Hold Second Quarter 2015 Financial Results Conference Call on Monday, August 10, 2015 2
... New England Journal of Medicine employs Quest Diagnostics, blood-based ... of blood specimens may detect abnormal white blood cells ... leukemia (CLL) develops, according to research published in the ... Journal of Medicine . The finding may lead to ...
... Pharmacyclics (Nasdaq: PCYC ) announced today ... investment by the principals of Pacific Biopharma Group, Ltd. ... Province, People,s Republic of China. The transaction was structured ... Pharmacyclics at $0.93/share. Robert Duggan, CEO of Pharmacyclics ...
Cached Medicine Technology:Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 2Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 3Blood Testing Identifies Abnormal Cells Up to Six Years Prior to Leukemia Diagnosis 4Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd. 2Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd. 3
... has greatly enhanced the stabilization ... Biomet Low Profile Tibial Nail ... treatment of unstable fractures, tibial ... pathologic or impending fractures but ...
Arthroscopic instrument system for instability and SLAP fixation....
Arthroscopic instrument system for instability and SLAP fixation....
Suture Cutter, Open Ended, Left Notch...
Medicine Products: